KEYNOTE B61 Extended Follow Up of Lenvatinib plus Pembrolizumab in nccRCC 1L

Opinion
Video

An expert discusses key data points from the KEYNOTE B61 extended follow up of Lenvatinib plus pembrolizumab in first line setting in non-clear cell renal cell carcinoma.

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
3 KOLs are featured in this series.